Overview / Abstract: |
STATEMENT OF NEED Gastric cancer is the third leading cause of cancer-related death worldwide. In the US, an estimated 27,510 new cases of gastric cancer are diagnosed annually, and 11,140 people die of the disease. Despite advances in prevention, diagnosis, and treatment, due to the molecular heterogeneity of gastric cancer, prognosis remains poor. The 5-year survival rate for all stages is 31%, with only 5% of those diagnosed with distant-stage disease surviving longer than 5 years. Given this poor prognosis and the fact that most gastric cancers are diagnosed at advanced stages, new screening and treatment strategies represent a significant unmet medical need. TARGET AUDIENCE Oncology physicians, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with gastric cancer. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: 1. Assess pathologic and molecular characteristics that can individualize treatment selection for patients with metastatic gastric cancer Note: The learning objectives listed above apply to nurse practitioners and registered nurses in addition to physicians. |
Expiration |
Mar 18, 2020 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Monograph, Online |
Credits / Hours |
1.0 |
Accreditation |
ACCME, ANCC |
Presenters / Authors / Faculty |
Jaffer A. Ajani, MD (Chairperson) Allyson J. Ocean, MD |
Sponsors / Supporters / Grant Providers |
This activity is supported by independent educational grants from Lilly and Taiho Oncology. |
Keywords / Search Terms |
i3 Health i3 Health, gastric cancer, esophagogastric cancer, gastrointestinal cancer, GI cancer, oncology, free cme, free ce, free cme ce, supportive care, ILNA points Free CE CME |